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North American birch species of the boreal forest contain significant amounts of pentacyclic 
triterpenes in their outer bark. Betulin (BE) and betulinic acid (BA), pentacyclic triterpenes readily 
extracted from outer birch bark, have been reported to exhibit a wide array of therapeutic effects, 
including selective inhibition against melanoma, and the inhibition of key enzymes involved in skin aging 
and melanogenesis. Despite their promising therapeutic effects and lack of toxicity towards healthy cells, 
their use in pharmaceuticals and cosmetics has been limited by their poor hydrosolubility. Ethosomes are 
lipid vesicles that have been successfully employed to encapsulate hydrophobic compounds and enhance 
their drug delivery and bioavailability. The aim of this study was to investigate the use of ethosomes as a 
delivery system for triterpenes and evaluate their anti-melanoma and anti-melanogenic effects. BE, BA, 
and a triterpene extract from Betula papyrifera (TE) were successfully incorporated into an ethosome for 
the first time and assessed for their anti-melanoma and anti-melanogenic effects in B16-F10 melanoma 
cells. Firstly, ethosomes containing BE, BA, or TE were prepared and characterized by their vesicle size, 
entrapment efficiency, and morphology. The cytotoxicity on B16-F10 melanoma cells was then explored. 
Lastly, the effect on cellular tyrosinase activity in B16-F10 cells was evaluated as a measure of anti-
melanogenic effect. The ethosomal triterpenes had mean vesicle sizes ranging from 3.67 – 5.11 µm and 
high entrapment efficiencies ranging from 93.25 – 95.76%. The ethosomal triterpenes showed significant 
cytotoxicity and higher in vitro anti-melanoma effects than triterpene solutions of equivalent 
concentration. BE-ethosomes showed an IC50 of 2.43 µM compared to 14.38 µM in BE solutions. BA-
ethosomes showed an IC50 value of 3.07 µM compared to 16.41 µM in BA solutions. TE (IC50 = 36.00  
µg/mL) showed cytotoxicity comparable to both BE and BA, but its effect was not improved by the 
ethosomal solution (IC50 = 43.51 µg/mL). BE, BA, and TE showed significant anti-melanogenic effect, 
inhibiting tyrosinase more effectively than the standard inhibitor kojic acid. These findings support the 
use of BE, BA, and TE as therapeutic agents and outlines their potential for topical and transdermal 
applications for the treatment of melanomas and skin aging. 
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Lay Summary  
 
Faculty and students in the Department of Biology are bound together by a common interest in 
explaining the diversity of life, the fit between form and function, and the distribution and abundance of 
organisms. This research was undertaken to better understand the functions and therapeutic potential of 
naturally occurring secondary metabolites produced by Betula papyrifera. Compounds such as betulin 
and betulinic acid have promising therapeutic potential and are readily extracted from low-value tree bark 
residues from the forestry industry, though are often over-looked on account of their poor hydrosolubility. 
By studying their in vitro biological effects on cancer cell populations, and attempting to enhance their 
delivery and bioavailability through novel drug delivery systems, these compounds may prove useful in 
the development of naturally sourced therapies to treat a range of human diseases. This work represents 
the first investigation of ethosomal nanocarriers as a delivery system for the triterpenes betulin and 
betulinic acid. Ethosomes were shown to incorporate these triterpene compounds with high efficiency, 
and enhance their anti-melanoma effect as demonstrated on B16-F10 melanoma cells. Further, the 
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BA - Betulinic acid 
BE - Betulin 
DMEM - Dulbecco’s modified Eagle’s medium 
DMSO – Dimethyl sulfoxide 
DNA – Deoxyribonucleic acid 
DPPC – Dipalmitoylphosphatidylcholine 
E-BE – Ethosomal betulin 
E-BA – Ethosomal betulinic acid 
E-TE – Ethosomal triterpene extract 
EE - Entrapment efficiency 
EtOH - Ethanol 
FBS – Fetal bovine serum 
HIV – Human immunodeficiency virus 
HPLC – High pressure liquid chromatography 
KA – Kojic acid 
L-DOPA – L-3,4-dihydroxyphenylalanine 
MTO – Mitoxantrone  
MTT - 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
PBS – Phosphate buffered saline 
PFTE - Polytetrafluoroethylene 
PPE – Porcine pancreatic elastase 
PR – Phenylethyl resorcinol 
RCF – Relative centrifugal force 
ROS – Reactive oxygen species 
SD – Standard deviation 
SEM – Scanning electron microscopy 
TE – The Actives Factory Triterpene Extract 
UV – Ultraviolet  
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1 - Introduction 
 Melanomas are a form of skin cancer characterized by early metastasis, rapid development, poor 
prognosis, and high mortality [1].  Despite early detection, surgical resection, and adjuvant therapies, the 
number of new cases and melanoma-related deaths continues to rise. Melanomas are one of the most 
therapy-resistant malignancies, and the few drugs that are approved for treatment of melanoma are often 
attributed with adverse side effects [2]. Betulin and betulinic acid are pentacyclic triterpenes found in 
significant quantities in the outer bark of Betula papyrifera and other species of North American birch. 
These compounds have been shown to exhibit selective cytotoxicity towards melanoma cells through the 
induction of apoptosis [3]–[5]. Accompanied by their lack in toxicity towards normal cells, these 
compounds represent promising anti-tumour agents. Despite their distinct bioactive properties, their use 
towards the development of pharmaceutical therapies and cosmetics has been limited by their poor 
aqueous solubility.  A drug delivery system which has been employed to enhance delivery and uptake of 
hydrophobic compounds is the ethosome. Ethosomes are a type of multilayer lipid vesicle characterized 
by their high ethanol content (20-45%), with high potential for the development of topical applications for 
skin disease therapies. Ethosomes are capable of encapsulating both hydrophilic and hydrophobic 
compounds, like triterpenes, and delivering them into the deep layers of the skin more efficiently than 
traditional liposomes [6], [7]. Furthermore, ethosomes have recently been shown to enhance the anti-
melanoma and anti-melanogenic effect of certain compounds [1], [8]. In this study, ethosomes containing 
betulin, betulinic acid, and a standardized triterpene extract from outer bark of Betula papyrifera 
developed by The Actives Factory were prepared and evaluated for their cytotoxicity towards melanoma 
cells and their anti-melanogenic effects. This work aims to add to the research being conducted on the 




1.1 – Skin Cancer and Melanoma 
Skin cancer is the most common form of cancer in Canada. The combined number of new 
melanoma and non-melanoma skin cancer cases in 2018 will nearly match that of the four major cancers 
combined (lung, breast, colorectal, prostate) [9] . The three main types of skin cancer, named according to 
the cell type from which they arise, are basal cell carcinoma, squamous cell carcinoma, and melanoma of 
the skin. The more common but less deadly skin cancers are known as non-melanoma skin cancers: 
squamous cell carcinoma and basal cell carcinoma. The third type, melanoma, is the deadliest form of 
skin cancer, and although it represents only 4% of all skin cancer diagnoses, it is responsible for 75% of 
all skin cancer-related deaths. Melanoma on its own accounts for about 3% of all new cancer cases, 
placing it in the top 10 cancers diagnosed in Canada [10]. Because most cases are identified early, it 
represents only 1.4% of all cancer deaths. Despite increased public awareness, the incidence rates of 
melanoma have increased for both males and females over the past decades, rising by 2.1% per year in 
males and 2.0% per year in females between 1992 and 2013 [10]. The slow-rising rates of melanoma 
mean greater efforts are required to encourage sun protection and restrict use of artificial tanning sources. 
Melanomas are malignant tumours that arise from neural crest-derived melanocytes which are 
pigmented cells found in the epidermis and sometimes the dermis [11]. The process in which melanocytes 
progress to malignant melanomas involves a series of steps, beginning with the development of benign 
naevocellular naevus, preneoplastic dysplastic naevus, primary melanoma, and finally metastatic 
melanoma [12]. The four types of melanoma are superficial spreading melanoma, nodular melanoma, 
lentigo maligna melanoma, and acral lentiginous melanoma [13]. The most common type is superficial 
spreading melanoma, which accounts for approximately 70% of reported melanoma cases, while nodular 
melanoma accounts for 15-30%, lentigo melanoma 4-10%, and acral lentiginous melanoma 2-8% of 




1.1.1 - Risk Factors 
The risk factors for development of cutaneous melanoma are both environmental and genetic. The 
predominant environmental factor leading to melanoma, as well as non-melanoma skin cancers, is 
exposure to UV radiation, which accounts for 90% of melanoma cases in North America [15]. The most 
at risk individuals are those who experience intermittent sun exposure, such as individuals who work 
indoors but spend free time outdoors and whose skin is not well-adapted to the sun, as well as those with 
a history of severe sun burns, as the risk of developing melanoma is increased two-fold in those who have 
had ten or more severe sun burns [16], [17]. Exposure to artificial UV radiation from tanning beds and 
sun lamps also increases the risk of developing melanoma, as UV light emitted from tanning beds was 
classified as a human carcinogen in 2009 by the World Health Organization International Agency for 
Research on Cancer [18]. Contrary to claims from the indoor tanning industry, artificial tanning is neither 
a safe or useful way to increase systemic vitamin D levels [19]. The use of indoor tanning beds can 
increase an individual’s risk of developing squamous cell carcinoma by 67%, basal cell carcinoma by 
29%, and melanoma by 20% [20], [21]. Skin pigment also plays an important role in melanoma 
susceptibility, as there is an inverse correlation between melanoma risk and the degree of skin colour 
from light to dark, which arises from the protective role that melanin plays against UV damage to human 
skin [22]. Features such as fair skin, freckling, blue or green eyes, blonde or red hair, are all risk factors 
for the development of melanoma [17], [23].  
1.1.2 - Treatment and Prevention 
 The key to skin cancer prevention is through minimizing exposure to harmful levels of UV 
radiation, which includes avoiding artificial sources of UV radiation such as tanning beds and using 
proper sun protection when exposed to sunlight. Current methods for the treatment of metastatic 
melanoma include surgery [24], isolated limb perfusion [25], cryotherapy [26], radiation therapy [27], 
BRAF inhibition [28], as well as several immunotherapies in various stages of drug development [29]–
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[32]. Although patients diagnosed with malignant melanoma have excellent prognosis when treated at 
early stages, current treatments such as chemotherapy and immunotherapy are unsatisfactory in managing 
advanced melanoma cases, and thus improved and/or combined treatments are required.  
1.2 - Skin Aging 
Aging is a complex phenomenon that has been defined by biologists as the sum of all changes 
that occur in a living organism throughout its life that contribute to the decreased ability to survive stress, 
functional impairment, and ultimately death [33]. Skin aging is determined by both intrinsic (genetic) and 
extrinsic (environmental) factors and is therefore defined by two types: chronological aging, and photo-
aging.  Chronological aging is determined primarily by intrinsic factors and hormonal status, while photo-
aging is the result of exposure to environmental aggressors such as UV radiation, chemical agents, and 
stress [34], [35].  Both types of aging leads to dry and thin skin, wrinkles, age spots, and degradation of 
the collagen and elastin fibers in the skin. Wrinkle and age spot formation are believed to be primarily 
induced by UV radiation, and therefore long-term skin care solutions for topical application are of great 
interest for physicians and patients alike.  
1.2.1 - Wrinkles  
The process of skin aging involves the deterioration of skin tissue and structural changes to the 
macromolecules of the extracellular matrix of the dermis [36]. Elastin is a major component the elastic 
fibers that form a candelabra type network in the papillary dermis, which give the skin its elastic 
properties but progressively degrade over time as a result of decreased synthesis and increased 
degradation of elastin fibers due to exposure to UV radiation [37]. Thus, over time, the skin loses its 
elasticity and wrinkles become more prevalent. The only enzyme that is capable of degrading elastin is 
elastase, and therefore inhibition of this enzyme can be considered a useful strategy for protecting against 
skin aging resulting from UV radiation [38]. 
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1.2.2 - Hyperpigmentation 
Another common condition observed in photo-aged skin are localized hyperpigmented regions 
known as age spots. Age spots are clinically diagnosed as solar lentigines, and represent a localized 
increase in pigmentation, which may be a result of increased number of melanocytes or an increase in 
melanin pigment [39]. Melanin is the pigment responsible for the colour of skin, hair, and eyes. It is 
produced in cells called melanocytes which are located in the bottom layer of the epidermis and middle 
layer of the eye through a process called melanogenesis. Tyrosinase, a multifunctional copper-containing 
enzyme, regulates melanogenesis within melanocytes. It catalyzes the hydroxylation of tyrosine to L-3,4-
dihydroxyphenylalanine (L-DOPA) and the oxidation of L-DOPA to dopaquinone, which is converted to 
melanin after a series of reactions involving cyclization and oxidative polymerizations [40]. Thus, 
tyrosinase is responsible for the pigmentation of skin, hair, and eyes in mammals. The over-activity of 
tyrosinase induced by UV radiation can lead to the development of both melanoma and age spots, and 
therefore one mechanism which has been employed to decrease pigmentation is inhibition of the enzyme 
tyrosinase by compounds such as hydroquinone, arbutin, and kojic acid [41]–[43]. Although these anti-
melanogenic agents and others like retinol (vitamin A) are currently used as topical agents to treat 
hyperpigmentation, they can often lead to adverse effects in the form of skin irritation, and raise concerns 
for safety regarding long-term exposure [44]. As a result, patients and consumers alike are increasingly 
shifting their interest towards the use of natural depigmenting agents for their high tolerability, efficacy, 
and easily accessible formulations.  
1.3 – North American White Birch (Betula papyrifera) 
The utilization of bioactive compounds from natural sources has long been an area of focus in 
research, but there has been little attention given to trees of the northern boreal forests. One tree which 
has garnered attention in the past few decades is white birch. Betula papyrifera, commonly known as 
white birch or paper birch, is a medium sized deciduous tree native to northern North America. It is 
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distributed throughout all provinces and territories in Canada, with the exception of Nunavut, as well as 
northern regions of the United States of America including Alaska. The Betula species exhibit various 
therapeutic properties and have been used in traditional medicines in many parts of the world throughout 
history. One of the more common uses was in the treatment of ailments relating to the bones such as 
arthritis, rheumatism, and gout, while the sap has been used to treat rashes, hepatitis, and scurvy [45]. The 
outer bark has also long been the subject of folk remedies. Birch bark oil has been used in folk medicine 
for the treatment of skin diseases such as eczema and psoriasis [46], while Native Americans prepared 
teas from the bark for the treatment of digestive tract infections [47]. The outer bark of boreal birch 
species has now been shown to contain considerable amounts pentacyclic triterpenes, a class of plant 
secondary metabolite with proven therapeutic properties. These compounds can account for upwards of 
35% of the dry weight of the outer bark, which is the highest quantity found in any known plant [48].  
The Canadian and American forestry industries produce massive amounts of residues annually in 
the form of stems, sawdust, leaves and bark from commercially managed species such as birch. Though 
rich in bioactive compounds such as triterpenes, these residues are typically burned as fuel to reduce 
energy costs. The current demand for these compounds is still growing, but in future years these 
compounds could very well satisfy requirements for pharmaceuticals, cosmetics, fungicides, biocides, as 
well as yet to be developed markets, since the supply of natural bark sources is virtually unlimited. 
Finding economical, naturally sourced products from abundant low-value raw materials such as forestry 
residues can bring added value to the forestry industry and the bioeconomy, while providing safe, 
effective, and natural alternatives for pharmaceutical and cosmetic development. 
1.4 - Birch Bark Triterpenes:  
Terpenes are a group of plant secondary metabolites that have been extensively researched due to 
their wide range of bioactive properties. Triterpenes, a class of terpene, consist of six isoprene units and 
arranged in complex cyclic structures [49]. Pentacyclic triterpenes consist of a 30-carbon skeleton 
7 
 
composed of 5 six-membered rings (ursanes and lanostanes) or 4 six-membered rings and 1 five-
membered ring (lupanes and hopanes) (Figure 1). Triterpenes are ubiquitously distributed throughout the 
Plant Kingdom with high potential as bioactives. Their physiological function in plants is believed to be 
as a defence against plant pathogens [48], which makes them an interesting candidate for potential 
defence against human and animal disease. Although factors such as their low aqueous solubility and 
relatively high molecular weight have traditionally limited their attractiveness for use in the drug industry, 
their established low toxicity and high efficacy supports their use in drugs, cosmetics, dietary 
supplements, biocides, and more [50]. 
The outer bark of boreal birch contains an extremely high content of pentacyclic triterpenes 
including betulin (BE), betulinic acid (BA), lupeol, betulinic caffeates, and betulinic aldehyde. Among 
triterpenes, BE is one of the most abundant in nature, and is responsible for the characteristic white colour 
of birch bark, where it is found in crystalline deposits in the outermost layers and nearly fills the interior 
of the peridermal cells. [51]. Betulin and betulinic acid have been shown to exhibit anti-inflammatory, 








1.5 - Betulin  
Betulin (3β-28-dihydroxylup-20(29)-ene), a pentacyclic lupane-type triterpene, was first isolated 
from the bark of white birch in 1788, making it one of the first natural products to be isolated and 
scientifically described (Figure 1) [48]. It occurs in a variety of plant species and in particularly high 
concentrations in the outer bark of many birch species including Betula papyrifera (white birch), Betula 
pendula (silver birch), Betula alba (downy birch), and Betula alleghaniensis (yellow birch). In these 
species, BE can account for 20-30% of the dry weight of the outer bark, with the levels influenced by a 
variety of factors including the species of birch, its regional location, and the overall health and age of the 
tree [52]. Though in lesser quantities, BE can also be found in the roots and leaves of birch species [53]. 
Like other members of the triterpene family, BE exhibits antifungal and antimicrobial effects, and likely 
serves as a defence to fungal and bacterial attack through the bark. Along with these properties, BE also 
exhibits a wide range of other properties important to human health including anti-inflammatory [54], 
anti-viral and anti-HIV[47], hepatoprotective [55], and anti-cancer activity [56], [57]. Despite its wide 
range of bioactivities, the anti-cancer and chemopreventive potential of BE has garnered the most 
attention. The cytotoxic and anti-proliferative effects of BE have been described for a variety of cell lines 
of human cancers (Table 1), with the degree of effect depending on the cancer cell type, ranging from 
strong inhibition of cell proliferation in human neuroblastoma cells (SK-N-AS) with an IC50 
(concentration of drug which results in 50% reduction in cell growth) value of 2.5 µM, to a far less 
pronounced effect against human myelogenous leukemia cells (K562) with an IC50 value of >250 µM. 
Furthermore, there is often a great deal of variation in the degree of inhibition of cell proliferation 
between studies on the same cell lines. For example, BE has been studied extensively on the A549 human 






Table 1: Cytotoxic effects of BE and BA on human and animal cancer cell lines. 
Compound Cancer Type Cell Line IC50 (µM) Reference 














































 Human breast adenocarcinoma  MCF-7 8.32 [67] 
 Human colorectal adenocarcinoma DLD-1 6.6  [63] 
Betulinic Acid Human lung carcinoma A549 10.3  [63] 



























 Human breast adenocarcinoma  MCF-7 >50 [68] 
 Human colorectal adenocarcinoma  DLD-1 15  [63] 
IC50 = concentration of drug at which cell growth was inhibited by 50% 
 
1.5.1 - Anti-Melanoma Activity  
The cytotoxic activities of BE against several melanoma cell lines have been tested with 
promising results. The IC50 values of BE in human melanoma cells SK-MEL-28 (16.2 µM) and G631 
(12.4 µM) [62], were similar to that of murine melanoma cells B16-F10 (13.8 µM) [63], but much lower 
than that of murine melanoma cells B16 2F2 (27.4 µM) [64] and human melanoma cells MEL-2 (45.2 
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µM) [5]. This would suggest that the anti-proliferative potential of BE is independent of whether the cell 
is of human or non-human origin. In another murine melanoma cell line, B16-4A5, BE showed a 52% 
reduction in viable cells compared to the control at a concentration of 10 µM [65], compared to moderate 
activity in epidermoid mouth carcinoma KB cells with an IC50 value >45 µM [5], and inactivity towards 
SK-MEL2 cells with an IC50 value >250 µM [66].  
1.5.2 - Mechanisms of Action 
The induction of apoptosis, a type of programmed cell death characterized by a series of complex 
biochemical events, is an essential mechanism for anti-cancer agents, and has been shown to be one of the 
mechanisms leading to the cytotoxic and anti-proliferative effects of BE [69]. Cytomorphological 
alterations such as cell rounding, chromatin condensation, membrane blebbing, nuclear 
condensation/fragmentation, and apoptotic body formation are indicative of cells undergoing apoptosis, 
and have been observed in cells treated with BE [61]. The treatment of murine melanoma B164A5 cells 
with BE resulted in nearly equivalent proportions of apoptotic and dead cells among affected cells [65]. In 
addition, a study by Mullauer et al. (2009) investigating the effect of BE on Jurkat cells revealed BE 
induces mitochondrial damage that leads to cytochrome C release and apoptosis [70].  
1.5.3 - Toxicity 
BE, like many other pentacyclic triterpenes, has shown no toxicity. The minimal lethal dose and 
median lethal dose (LD50) in mice were reported as 6500 mg/kg and 9000 mg/kg, respectively [71]. 
Although there have been no published clinical trials using BE to treat cancer thus far, there have been 
studies using birch bark extract to treat actinic keratoses which have shown promising results [72], [73]. 
Actinic keratoses represent early and non-invasive squamous cell carcinoma induced by exposure to UV 
radiation in sunlight, and should be treated in order to prevent the development of non-melanoma skin 
cancers [74]. Huyke et al. (2009) incorporated a birch bark extract composed of 87% triterpenes (80% 
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BE) into an oleogel, which following a three-month treatment period resulted in >75% clearing of lesions 
in 86% of the patients, and 100% clearing of lesions in 64% of the patients [73].  
1.6 - Betulinic Acid  
Betulinic acid (3β-hydroxylup-20(29)-ene-28-oic acid), a C-28 carboxylic acid derivative of 
betulin, is potentially the most-studied of all pentacyclic triterpenes and has garnered significant attention 
in recent years due to its wide array of biological effects including anti-inflammatory, anti-HIV, and anti-
cancer activities. It was first described by Retzlaff in 1902 as an unknown compound extracted from 
Gratiola officinalis [75], and later identified and named in 1939 by Robertson et. al [76]. It is found in a 
variety of plants, but much like BE, it occurs in particularly high quantities in the outer bark of white 
birch and other members of the Betulaceae family. Other reported sources of betulinic acid include 
Ziziphus spp. (Rhamnaceae) [3], Diospyros spp. (Ebenaceae) [77], Syzygium spp. (Myrtaceae) [78], 
Uapaca spp. (Euphoribiaceae) [79], and Paeonia spp. (Paeoniaceae) [80]. Unlike BE, the quantities of 
naturally occurring BA in plants have proven to be quite low. The synthesis of BA from BE, which is 
available in sufficient quantities from botanical sources, has been employed to meet the demands of BA 
for biological and clinical testing. Though earlier methods of synthesis gave low yields and small-scale 
preparations, improved methods developed in the past decade have led to simpler, more cost-effective 
routes of synthesis that can be achieved at an industrial scale [81], [82]. BA was initially discovered as a 
highly selective inhibitor of human melanoma growth through the induction of apoptosis, however 
subsequent studies reported anti-cancer activity against several other types of cancer including 
neuroectodermal tumors such as neuroblastoma, medulloblastoma, and glioblastoma, as well as 
carcinomas of the head, neck, colon, breast, lung, prostate, ovaries, and cervix [83]–[87]. 
1.6.1 - Anti-melanoma Activity  
 BA has been shown to have strongly selective anti-tumor activity against human and animal 
melanoma cells [88]. In a study of lupane-type triterpenes against murine melanoma (B16-F10), BA 
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showed similar anti-proliferative activity to BE, with IC50 value of 16.1 µM (compared to 13.8 µM for 
betulin) [63]. BA exhibited higher anti-proliferative activity when tested against human melanoma cell 
lines G361 and SK-MEL-28, with IC50 values of 5.2 µM and 6.5 µM, respectively [62]. In the same 
study, it was reported that the carbonyl group at C-17, and not the carboxylic acid group as previously 
suggested, plays an essential role in these inhibitory activities through the inhibition of topoisomerase I, 
an enzyme essential in the replication of DNA.  
1.6.2 - Mechanisms of Action 
BA’s biological activity stems from several mechanisms, including the induction of apoptosis, 
antiangiogenesis, cell cycle arrest, immunoregulation, as well as autophagy induction [89]–[92]. There 
have been many studies demonstrating BA’s ability to trigger apoptosis in cancer cells through disruption 
of mitochondrial membrane potential, the production of reactive oxygen species (ROS), as well as 
permeability transition pore openings which results in the release of mitochondrial apogenic factors, 
caspase activation, and DNA fragmentation [93]. The in vitro incubation of BA with melanoma cells led 
to the appearance of surface blebbing and cytoplasmic shrinking, both of which are characteristic of cells 
undergoing apoptosis [3].  
1.6.3 – Toxicity  
BA has been reported to show remarkably low toxicity, with no toxic effect in mice at 
concentrations as high as 500 mg/kg, in which doses were given intraperitoneally every fourth day for a 
total of six treatments [3]. Similarly, doses of 200 and 400 mg/kg  of BA administered to rats showed no 
evidence of toxicity [94]. Several studies have also demonstrated that normal cells including human skin 
fibroblasts, peripheral blood lymphocytes, and melanocytes are much more resistant to BA than cancer 




1.7 - The Actives Factory Triterpene Extract  
The Actives Factory Triterpene Extract (TE) is a natural extract product manufactured by The 
Actives Factory, an active-ingredient manufacturer with a production facility located in Two Harbors, 
Minnesota, USA. They specialize in the extraction, isolation, purification, and synthesis of compounds 
such as betulin, betulinic acid, lupeol, and betulin caffeates from the outer bark of North American birch 
bark (Betula papyrifera) using unique extraction and processing technologies initially developed at 
University of Minnesota’s Natural Resources Research Institute. Their triterpene extract is produced from 
the outer bark of Betula papyrifera and is especially suited for cosmetic and nutraceutical development, 
and contains a mixture of triterpenes including BE, BA, lupeol, betulinic aldehyde, and betulinic caffeates 
(Table 1.2). All birch bark used by The Actives Factory is paper milling waste product sourced from 
sustainably managed and harvested trees.  
Table 2: Composition of The Actives Factory Triterpene Extract.  
Compound Content 
Betulin 65% 
Betulinic Acid 7% 
Lupeol 7% 
Betulinic Caffeates 19% 
Betulinic Aldehyde 2% 
Other <0.5% 
 
1.8 – Anti-aging and Anti-melanogenic Effects of Birch Bark Triterpenes 
Birch bark triterpenes have also been shown to exhibit significant inhibitory activity against key 
enzymes involved in skin aging such as elastase, responsible for development of wrinkles, and tyrosinase, 
the key enzyme involved in melanogenesis and the development of hyperpigmentation/age spots. 
Compounds capable of counteracting these enzymes can be considered useful in skin-care and anti-aging 
formulations. In a study of elastase inhibitory properties of triterpenes extracted from Meliosma oldhamii, 
a deciduous tree native to China, Japan, and Korea, BE was shown to have an IC50 value of 88.8 µM 
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against porcine pancreatic elastase (PPE), comparable to the positive control ursolic acid (IC50 = 62.4 µM). 
BA has also been shown to inhibit elastase, with IC50 value of 47.3 µM against PPE in a study of 
compounds extracted from Callistemon lanceolatus, a species of bottlebrush [97]. Interestingly, in a study 
by Royer et al. (2013) of hot water and ethanol extracts of six Canadian forest species, the ethanolic 
extract of yellow birch (B. alleghaniensis) was the only extract able to completely inhibit elastase (IC50 = 
0.7 mg/mL), outperforming the positive control Oligopin® (IC50 = 1.0 mg/mL), a commercial 
standardized pine bark extract used in cosmetics and natural health products [34], [98]. The anti-
melanogenic effects have also been well-studied in triterpenes, represented by their ability to inhibit 
tyrosinase, the key enzyme involved in melanogenesis. In a study of compounds extracted from chaga 
mushroom (Inonotus obliquus), a fungus that grows on trunks of birch species, BE was shown to inhibit 
cellular tyrosinase in B16 melanoma cells more effectively than the positive control kojic acid with IC50 
values of 5.13 µM and 6.43 µM, respectively. BA extracted from Rhododendron collettianum (Ericaceae) 
has also been reported to be a strong inhibitor of tyrosinase activity, with an IC50 value of 2.14 µM against 
mushroom tyrosinase, which also was significantly more effective than the positive control kojic acid 
(IC50 = 16.67 µM) [99].  
 
1.9 - Transdermal Drug Delivery 
The skin is the largest and most accessible organ of the human body, and thus provides a 
promising route for drug administration. Transdermal drug delivery offers several advantages over oral 
and intravenous routes of administration, including the avoidance of first-pass metabolism by the liver, 
controlled delivery, reduced dosing frequency, it is non-invasive, and can be self-administered [100], 
[101]. The main barrier to transdermal drug delivery is the outermost layer of the skin, the stratum 
corneum, which limits bioavailability and prevents the penetration of many drugs to the deeper layers of 
the skin where they are needed [102]. In order to combat this natural skin barrier, special carriers are 
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required to transport drugs through the skin. One approach for improving skin penetration is the use of 
vesicular delivery systems such as liposomes and ethosomes.  
1.10 - Liposomes 
Liposomes are the most investigated nanocarrier for targeted drug delivery, and have been 
employed to improve a wide array of biomedical therapies by stabilizing compounds, overcoming 
obstacles involved with cellular uptake, and improving biodistribution of compounds [103]–[105]. They 
are spherical vesicles that consist of phospholipid bilayers arranged in one or multiple concentric layers 
around an aqueous core (Figure 2). As a result of their structure, liposomes are able to entrap hydrophilic 
drugs in their aqueous core and hydrophobic drugs in their bilayer membrane. Because of their 
composition, liposomes are biocompatible and biodegradable, and are considered to be, for the most part, 
pharmacologically inactive with low intrinsic toxicity [104]. They facilitate the passage of drugs through 
biological barriers and cellular membranes by either fusing with membranes and releasing their contents, 
or being taken up directly by the cell through the process of endocytosis [106]. Although many reports in 
the past focused on enhancing percutaneous delivery through the use of liposomes, it is now generally 
agreed that they are of little to no value as carriers for transdermal drug delivery because they are not able 
to penetrate into the deeper layers of the skin, and remain confined in the stratum corneum [107].  
1.11 – Ethosomes for Transdermal Drug Delivery  
Ethosomes (Figure 2) are a variation of the well-established drug carrier liposomes, differing 
mainly in that they contain relatively high concentrations of ethanol (10-50% v/v) in addition to 
phospholipids and water [108]. They were first described in 1997 by Touitou et al. [109], and since then 
have been used more and more in the scientific and pharmaceutical fields. Ethosomes range in size from 
tens of nanometers (nm) to a few micrometers (µm), and have been reported to improve the skin delivery 
of several drugs [1], [110]. The high concentration of ethanol is what makes ethosomes unique and gives 
them their enhanced penetration properties. Ethanol is a known penetration enhancer, which acts by 
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disturbing the skin lipid bilayer organization [111]. Additionally, inclusion of ethanol in the vesicular 
membrane results in a less densely packed membrane, allowing for more malleable and deformable 
vesicles compared to conventional vesicles such as liposomes. 
 
Figure 2: Schematic representation of an ethosome. 
1.11.1 - Mechanism of Ethosomal Drug Delivery 
Touitou et al. suggested a synergistic mechanism between ethanol, the vesicles, and the lipids of 
the skin [108].  It is proposed that the first part of the mechanism is due to the ethanol effect, in which the 
ethanol intercalates with the polar head group environment and increases the permeability of the stratum 
corneum, effectively increasing its fluidity and decreasing its density. This is followed by the ethosome 
effect, which involves the penetration of the lipid through the opening of new pathways as a result of the 
malleability and fusion of ethosomes with skin lipids, allowing for release of drugs into deep layers of 
skin. This mechanism was later confirmed in a study of the dermal and intracellular deliver of ethosomes 
containing bacitracin, a polypeptide antibiotic [112]. 
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In a similar study by the same author, three different fluorescent probes were incorporated into 
ethosomes, hydroethanolic solutions, and liposomes, and the intracellular presence of the probes was 
detected by confocal laser scanning microscopy (CLSM) and fluorescence-activated cell sorting (FACS) 
following treatment on mice fibroblasts [113]. CLSM micrographs showed that ethosomes facilitated the 
penetration of all three probes into the cells as evident from the presence of high-intensity fluorescence. 
When incorporated into hydroethanolic solution or liposomes, almost no fluorescence was detected.  
1.11.2 – Effects of Constituents  
There are several components which have been used in ethosomal systems, and while ethanol and 
a phospholipid are present in all ethosome formulations, several other optional components, such as 
cholesterol and penetration enhancers like Tweens and Spans are often included in formulations to 
achieve specific vesicular properties. Ethanol, as mentioned, is a penetration enhancer, and has been 
reported to effect the size, stability, entrapment efficiency, and skin permeability of ethosomes, and is 
usually found in concentrations ranging from 10-50% [108], [114]. It is generally agreed that as ethanol 
concentration increases, the size of vesicles decreases [107], [115]. However, increasing ethanol 
concentration above optimum levels will lead to a poor entrapment efficiency due to a leaky bilayer and 
further increment of ethanol concentration will lead to solubilization of vesicles. Reports have suggested 
that the reduced size of ethosomes due to the presence of ethanol is a result of interpenetration of the 
ethanol hydrocarbon chain in the vesicular bilayer, leading to reduced membrane thickness, while other 
studies have suggested the modified net charge that ethanol confers to the vesicles provides some degree 
of steric stabilization, leading to decreased vesicle size [112], [115]. Phospholipids are one of the main 
components of ethosomal systems, and based on the type and concentration used, will influence the size, 
entrapment efficiency, stability, and penetration properties of the vesicular system. Several types and 
brands of natural and synthetic phospholipids have been employed in ethosome formulations, including 
dipalmitoylphosphatidylcholine (DPPC) [6], dipalmitoylphosphatidylglycerol (DPPG) [116], L-α-
phosphatidylcholine from soybean or egg yolk (PC) [117], Phospholipon 90G [118], Lipoid S100 [119], 
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Lipoid E80 [120], and others. Generally, phospholipid concentrations ranging from 0.5%-5% are used in 
ethosome formulations, with vesicular size generally increasing in relation to increasing phospholipid 
concentration [114], [117]. Increasing the phospholipid concentration will also increase the entrapment 
efficiency of the formulation to a certain a point, after which further increment in phospholipid 
concentration will have no effect. Cholesterol is a rigid steroid molecule which is naturally present in 
biological membranes and is commonly included in the formulation of liposomes and ethosomes. Its 
incorporation into ethosomal formulations has been reported to increase stability and entrapment 
efficiency by preventing membrane leakage and reducing vesicular permeability [100]. In addition, it has 
been reported to increase vesicular size of ethosomes in some cases, as well as increase rigidity [107]. 
The inclusion of edge activators and penetration enhancers has been widely employed in the 
preparation of ethosomes to enhance penetration and stability of formulations. Penetration enhancers 
include oleic acid, dimethyl sulfoxide (DMSO), and L-menthol, which have been reported to influence 
vesicular size and elasticity as well as increase skin permeation by acting on the stratum corneum [121], 
[122]. Edge activators are typically surfactants, and include sodium dodecyl sulfate (SDS), polyethylene 
glycol (PEG), as well as Tweens and Spans and their corresponding grades (80, 60, 40 and 20). Tween-80 
is a non-ionic surfactant and is one of the most commonly used edge activators in ethosomal and 
liposomal formulations. It is typically used in concentrations of 10-50% of the total phospholipid 
concentration, and has been reported to reduce vesicular size and improve the stability and skin-
permeation properties of ethosomal systems [117], [121], [123]. These effects are attributed to Tween-
80’s solubilizing properties which prevent vesicle fusion and increase the flexibility of the vesicles. It is 
worth noting that ethosomes containing an edge activator or penetration enhancer are often referred to in 
literature as “transethosomes”, first reported by Song et al. in 2012 in an attempt to combine advantages 
of classic ethosomes and deformable liposomes (transferosomes) [121]. However, there is still no clear 




1.11.3 - Clinical Applications  
Ethosomes have been used to enhance the therapeutic effect of a variety of compounds with 
promising results. Although the majority of published studies examine ethosomes in their initial 
suspension form, the systems usually need to be incorporated into a suitable vehicle for dermal or 
transdermal delivery due to the high concentration of alcohol and poor adhesive properties of ethosome 
solutions. The incorporation into a secondary vehicle for transdermal drug delivery prevents ethanol 
evaporation, prolongs contact time with the skin, and improves stability of the system and patient 
compliance. Ethosomes have recently been incorporated into gels [124], [125], transdermal patches [126], 
[127], and creams [128]. Gels are by far the most common vehicle for the delivery of ethosomes and are 
produced by incorporating a gel-forming agent such as Carbopol or hydroxypropyl methylcellulose. 
These polymers, along with their related grades (Carbopol 934, Carbopol 940, Carbopol 974, etc.) are 
compatible with ethosomal systems and provide the necessary mechanical properties in terms of viscosity 
and bio-adhesion. Yu et al. recently incorporated mitoxantrone (MTO) into an ethosome gel using 
hydroxypropyl methylcellulose as a gel forming agent and evaluated its cytotoxicity towards B16 
melanoma cells [1]. The ethosome gel outperformed hydroethanolic solutions of MTO in terms of both 
transdermal permeation and anti-cancer effect.  
Ethosomes have also recently been used to improve the skin-lightening effect of phenylethyl 
resorcinol (PR), a phenolic compound with tyrosinase inhibition activity. Limsuwan et al. (2017) 
incorporated PR into ethosomes and evaluated the effect on cellular tyrosinase activity in B16 melanoma 
cells and pig skin compared to PR delivered in liposomes, 20% propylene glycol solutions, and 30% 
hydroethanolic solutions [8]. Ethosomes consistently exhibited higher tyrosinase inhibition when 
compared to other formulations in both the B16 melanoma cells and the pig skin. These findings 
demonstrate that ethosomes are capable of delivering therapeutic agents into the skin efficiently and have 





I: Incorporate birch bark triterpenes into ethosomes and characterize ethosomes based on their size 
and entrapment efficiency. Ethosomal formulations containing BE, BA, and TE will be prepared based 
on an optimized formulation. Vesicle size of ethosomes will be measured using diffraction laser particle 
size analysis, entrapment efficiency will be determined using centrifugation method with high pressure 
liquid chromatography (HPLC), and the morphology and structure of ethosomes will be determined by 
visualizing the ethosomes using scanning electron microscopy (SEM). 
 
 
II: Evaluate the anti-melanoma effect of ethosomal triterpenes on B16-F10 cells. Viability of B16-
F10 cells treated with ethosomal triterpenes (E-BE, E-BA, E-TE) will be evaluated by MTT assay and 
compared to cells treated with free form triterpenes (BE, BA, TE) in ethanolic solutions. 
 
 
III: Evaluate the anti-melanogenic effect of ethosomal triterpenes in B16-F10 cells. The cellular 
tyrosinase activity of B16-F10 cells treated with ethosomal triterpenes (E-BE, E-BA, E-TE) will be 
measured by monitoring the treated cells’ ability to convert L-DOPA to dopaquinone and compared with 







2 - Materials and Methods 
2.1 - Materials 
Cholesterol, Tween-80, Triton X-100, Dulbecco’s modified Eagle’s medium (DMEM), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 3,4-dihydroxy-L-phenylalanine (L-
DOPA), 3-isobutyl-1-methylxanthine (IBMX), and kojic acid were obtained from Sigma-Aldrich (St. 
Louis, MO, USA). Dipalmitoyl phosphatidylcholine (DPPC) was obtained from Transferra Nanosciences 
(Burnaby, BC, Canada). HyClone fetal bovine serum (FBS) was obtained from Fisher Scientific 
(Hampton, NH, USA).  Betulin (BE), betulinic acid (BA), and The Actives Factory Triterpene Extract 
(TE) were supplied by The Actives Factory (Hopkins, MN, USA). B16-F10 murine melanoma cell line 
(CRL-6475) was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). 
 
2.2 - Preparation of Ethosomes Containing Triterpenes 
Ethosomes were prepared using the Cold Method with slight modification [6]. The lipid phase 
consisted of appropriate amount of drug (20 mg), 0.2-0.4% w/v DPPC, 1.29 mM cholesterol, and 1 
µL/mL Tween-80 dissolved in 100% ethanol (3-5 mL) maintained at 30 °C under magnetic stirring at 
1200 RPM in a well-sealed glass bottle. Into this solution, the aqueous phase consisting of 0.01 M 
phosphate buffered saline (pH 7.4) maintained at 30°C in a separate vessel was added drop-wise with the 
help of a syringe. The mixture was stirred for an additional 10 minutes following the addition of aqueous 
phase and allowed to cool to room temperature. The mixture was then sonicated (20 W) for 15 minutes 
using a digital probe sonicator (Branson Ultrasonics Corporation, Danbury, CT, USA). Temperature of 
mixture was maintained at approximately 20 °C throughout sonication using a water bath. To remove 
undissolved components, solutions were filtered through 10 µm nylon filters (Micron Separations Inc., 
Westborough, MA, USA). The ethosomes produced were stored at 4°C until use. All formulations were 
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prepared in triplicate (n = 3). For optimization study, betulin was used as the model drug in all 
formulations. In Table 1, the composition corresponding to all formulations have been reported.  
Table 3: Composition of ethosome formulations used in optimization study. Ethosomes were 
prepared by Cold Method and contained 1.29 mM cholesterol, 4.52 mM betulin, and 1 µL/mL Tween-80.  
Formulation DPPC (% w/v) Ethanol (% v/v) 0.01 M PBS (% v/v) 
A 0.2 30 70 
B 0.2 40 60 
C 0.2 50 50 
D 0.3 30 70 
E 0.3 40 60 
F 0.3 50 50 
G 0.4 30 70 
H 0.4 40 60 
I 0.4 50 50 
 
2.3 - Characterization of Ethosomes Containing Triterpenes: 
2.3.1 - Determination of Vesicle Size of Ethosomes: 
Vesicle size was determined by laser diffraction using a Microtrac S3500 Particle Size Analyzer 
(Microtrac, Largo FL, USA). The average of three measurements was taken for triplicate batches of each 
formulation. Volumetric distributions were used for calculation of mean particle size. All measurements 
are presented as mean ± standard deviation (n = 3). Vesicle sizes are reported as the mean value of a 
volumetric distribution of the data. 
2.3.2 - Determination of Entrapment Efficiency of Ethosomes: 
The entrapment efficiency (EE) of each ethosome formulation was determined by centrifugation 
method. The formulations were centrifuged at 16,000 RCF for 1 hour at 4 °C using a Sorvall Legend 
Micro 17R Centrifuge (Thermo Fisher Scientific, Waltham, MA, USA), after which supernatant was 
23 
 
collected and diluted with 100% ethanol. The amount of drug contained in the diluted supernatant was 




 x 100                               
 
Where Qt = the amount of drug added and Qs = amount of drug detected in supernatant.  All 
measurements are presented as mean ± standard deviation (n ≥ 3). 
                       
2.3.3 - Determination of Triterpene Content using High Performance Liquid Chromatography (HPLC): 
Betulin, betulinic acid, and The Actives Factory Triterpene Extract were analyzed by Agilent 
1260 Series HPLC at 25 °C with a Poroshell 120 EC-C18 2.7 µm column (4.6 x 100 mm) (Agilent 
Technologies, Santa Clara, CA, USA). The flow rate was 1.0 mL/min with the mobile phase consisting of 
acetonitrile and water at a ratio of 86:14 (v/v). The column eluent was monitored with a UV detector at 
200 nm. 
2.3.4 - Visualization of Ethosomes with Scanning Electron Microscopy (SEM): 
For visualization by SEM, ethosome formulations were diluted 1:50 with 40% ethanol in 0.01 M 
PBS and filtered through 0.45 µm PTFE filters, after which 10.0 µL of the diluted vesicular system was 
homogenously spread onto a glass stub and left to dry overnight at room temperature. The following day, 
samples were carbon coated using an Edwards Auto 306 carbon coater (Edwards, Crawley, UK) 
(Lakehead University Instrumentation Lab) and observed under a Hitachi SU-70 Schottky FE-SEM at an 





2.4 - Cell Culture 
B16-F10 murine melanoma cells (American Type Culture Collection # CRL-6475) were 
maintained in Costar 0.2 µm vent cap culture flasks (Corning, Corning, NY, USA) with standard 
Dulbecco’s modified Eagle’s medium (Sigma-Aldrich) supplemented with 10% heat inactivated fetal 
bovine serum (HyClone Laboratories, Logan, UT, USA) and 1% penicillin/streptomycin (100 U/mL and 
100 µg/mL). Cultures were incubated at 37 °C in a humidified atmosphere containing 5% CO2 until 
approximately 90% confluence. Cells were subcultured every 48 hours by trypsinization. 
2.5 – Preparation of Ethosomal and Ethanolic Triterpene Solutions for Cell Treatment 
Prior to cell treatment, ethosomal formulations were filtered through 0.8 µm nylon syringe filters 
and drug content was re-measured with HPLC to determine final triterpene concentration of filtered 
solutions. From these, stock solutions of 3 mM were made for each ethosome formulation (BE-
ethosomes, BA-ethosomes, TE-ethosomes), and diluted with DMEM to form specific treatment 
concentrations (0.1 µM, 1 µM, 10 µM, 20 µM). Blank ethosomes were diluted to the same extent to serve 
as solvent controls for cell treatment. For ethanolic solutions, triterpenes (BE, BA, TE) were dissolved in 
100% ethanol to form stock solutions of 10 mM, which were then diluted with DMEM to form specific 
treatment concentrations (0.1 µM, 1 µM, 10 µM, 20 µM). Final ethanol concentration in cell treatments 
did not exceed 0.25%. 
2.6 - Measurement of Cell Viability  
Cell viability was determined using MTT assay, in which mitochondrial and cytosolic 
dehydrogenases of viable cells reduce yellow MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) to purple formazan that can be measured spectrophotometrically [129]. B16-F10 murine 
melanoma cells were seeded at 1.0 x 104 cells/well into sterile 96-well flat-bottom plates (Corning) for 24 
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hours, then incubated with test substances for 48 hours at 37°C in a humidified atmosphere containing 5% 
CO2. During final 4 hours of treatment, 20 µL of MTT solution (5 mg/mL dissolved in PBS) was added to 
each well. Following treatment, media was removed and 150 µL of dimethyl sulfoxide (DMSO) was 
added to solubilize formazan crystals. After gentle shaking for 10 minutes, absorbance was measured 
spectrophotometrically at 570 nm using PowerWave XS Microplate Spectrophotometer (BioTek, 
Winooski, VT, USA). The viability of treated wells was compared to that of control wells, which were 
taken to have 100% viability.  
2.7 - Measurement of Cellular Tyrosinase Activity 
Cellular tyrosinase activity was determined by the method described by Tomita et. al with some 
modification [130]. B16-F10 murine melanoma cells were seeded at 1.0 x 104 cells/well into sterile 96-
well flat-bottom plates (Corning) for 24 hours. Following incubation with test substances in the presence 
of 100 µM 3-isobutyl-1-methylxanthine (IBMX) for 48 hours, cells were washed with ice-cold PBS and 
lysed with PBS containing 1% Triton-X (80 µL/well), then frozen at -80°C for 30 minutes. After thawing 
and mixing, 20 µL of 10 mM L-DOPA was added to each well, and cells were incubated for 2 hours at 
37°C, after which absorbance was measured at 490 nm using PowerWave XS Microplate 
Spectrophotometer (BioTek). The relative activity of treated wells was compared to that of control wells, 









3 - Results 
3.1 - Optimization of Ethanol and DPPC Concentration in Ethosome Formulations 
Initially, an optimization study was carried out to determine the most suitable phospholipid and 
ethanol concentration for the ethosomal system. Ethosome formulations containing 0.2-0.4% w/v DPPC 
and 30-50% v/v ethanol were prepared as described and characterized based on their mean vesicle size 
and entrapment efficiency (Table 4). Betulin was used as the model drug for all nine formulations. Ranges 
of phospholipid and ethanol content were selected based on preliminary work not shown, in which it was 
determined the inclusion of DPPC at concentrations greater than 0.5% w/v resulted in the formation of a 
colloidal gel upon sonication, whereas concentrations below 0.2% resulted in vesicles inconsistent in size 
and morphology. The inclusion of <30% v/v of ethanol was insufficient to solubilize components of the 
lipid phase, whereas inclusion >50% v/v ethanol resulted in disruption of the lipid vesicles. Ethosome 
formulations in the optimization study ranged in mean vesicle size from 3.67-15.08 µm, with entrapment 
efficiencies ranging from 88.67-98.68%. With the exception of formulation F, the mean vesicle size 
decreased in relation to increasing ethanol concentration. Entrapment efficiency increased in relation to 
increasing ethanol concentration with the exception of formulations containing 0.2 % w/v DPPC (A-C), 
in which the opposite trend was observed. When DPPC concentration was increased from 0.2 % w/v to 
0.3 % w/v, the mean vesicle size of formulations decreased, but increased when the DPPC concentration 
was further increased to 0.4 % w/v. For formulations containing 30% and 40% ethanol, the entrapment 
efficiency decreased with increasing DPPC concentration, but the opposite trend was observed for 
formulations containing 50% ethanol, in which entrapment efficiency increased in relation to increasing 
DPPC concentration. Based on the desired characteristics of a stable vesicle formulation with a size of ≤5 
µm and an entrapment efficiency greater than 90%, formulation E (0.3% w/v DPPC, 40% v/v ethanol) 
was chosen for all further vesicle preparations which was determined to have a mean vesicle size of 3.67 
µm and an entrapment efficiency of 95.76%.  
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3.2 - Formulation and Characterization of Ethosomes Containing BE, BA, and TE 
Using formulation E from the optimization study (0.3% w/v DPPC, 40% v/v ethanol), ethosomes 
containing betulin (BE), betulinic acid (BA) and The Actives Factory Triterpene Extract (TE) were 
prepared and characterized in terms of mean vesicle size and entrapment efficiency (Table 5). A blank 
ethosome (no drug content) was also prepared for comparative purposes. The mean vesicle sizes of 
ethosomes containing BE, BA, and TE ranged from 2.57–5.11 µm, while the entrapment efficiencies 
ranged from 93.25-95.76%. The blank ethosome was determined to have a mean vesicle size of 3.79 µm. 
 To determine the structure and surface morphology of BE-ethosomes, BA-ethosomes, and TE-
ethosomes, formulations were diluted 50:1, filtered through 0.45 µm PTFE filters, and observed using 
SEM (Figure 2-5). For all ethosomal systems, the presence of larger vesicles ranging from 200-500 nm 
(Figure 2-5-A) distributed among smaller, uniformly-sized ethosomes approximately 50 nm in size 
(Figure 2-5-B) was observed. The ethosomes were mainly spherical in shape, with increasing irregularity 
in shape present among the larger vesicles. The smaller vesicles showed much higher uniformity in terms 
of shape and size.  
Table 4: Vesicle size and entrapment efficiency of ethosomes produced in optimization study. 
Ethosomes were prepared containing 2 mg/mL (4.52 mM) betulin, 1.29 mM cholesterol, 1.0 µL/mL 
Tween-80, and 0.01 M PBS up to 100% v/v.  
Formulation DPPC (%w/v) Ethanol (% v/v) Vesicle Size (µm) Entrapment 
Efficiency (%) 
A 0.2 30 10.21 ± 3.63 98.40 ± 0.28 
B 0.2 40 8.49 ± 1.45 96.33 ± 0.73 
C 0.2 50 8.27 ± 1.76 93.97 ± 7.74 
D 0.3 30 6.67 ± 2.54 91.25 ± 1.34 
E 0.3 40 3.67 ± 0.10 95.76 ± 0.85 
F 0.3 50 4.22 ± 0.84 97.66 ± 0.72 
G 0.4 30 15.08 ± 2.07 88.67 ± 4.15 
H 0.4 40 11.00 ± 1.40 93.65 ± 4.34 
I 0.4 50 6.67 ± 1.30 98.68 ± 0.68 
Each data represents the mean ± SD (n=3) 
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Table 5: Vesicle size and entrapment efficiency of ethosomes containing birch bark triterpenes.  
Ethosomes were prepared with 1.29 mM cholesterol, 1.0 µL/mL Tween-80, and 0.01 M PBS up to 100% 
v/v and 2 mg/mL of either BE (4.52 mM), BA (4.38 mM), or TE.  
Compound DPPC (% w/v) Ethanol (% v/v) Vesicle Size (µm) Entrapment 
Efficiency (%) 
E-BE 0.3 40 3.67 ± 0.78 95.76 ± 0.85 
E-BA 0.3 40 5.11 ± 0.52 93.33 ± 0.73 
E-TE 0.3 40 2.57 ± 0.33 93.25 ± 1.34 
Blank 0.3 40 3.79 ± 0.41 - 
Each data represents the mean ± SD (n=3) 
 
    
 
Figure 3: Scanning electron micrographs of BE-ethosomes. BE-ethosomes were carbon coated and 
visualized with SEM at A) 100,000 X and B) 50,000 X.  
 
    
Figure 4: Scanning electron micrographs of BA-ethosomes. BA-ethosomes were carbon coated and 
visualized with SEM at 50,000 X. 
29 
 
    
Figure 5: Scanning electron micrographs of TE-ethosomes. TE-ethosomes were carbon coated and 
visualized with SEM at 50,000 X.  
 
    
Figure 6: Scanning electron micrograph of blank ethosome. Blank ethosomes were carbon coated and 
visualized with SEM at A) 180,000 X, and B) 100,000 X. 
 
 
3.3 - Effect of E-BE and BE on Viability of B16-F10 Melanoma Cells 
To assess the effects of BE, BA, and TE on B16-F10 melanoma cells, cells were treated with 
increasing concentrations of the triterpenes delivered in both ethosomes as well as their free form in 
ethanolic solutions (0.1, 1, 10, 20 µM) for 48 hours. For both E-BE and BE, the viability of B16-F10 
melanoma cells decreased in a concentration-dependent manner relative to control cells as determined by 
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the MTT colourimetric assay (Figure 7). A moderate effect on cell viability was observed even at the 
lowest concentration (0.1 µM), with ~30% cell death in cells treated with E-BE, and ~15% cell death in 
cells treated with BE. The relative viability of cells treated with E-BE was lower for all concentrations, 
with 40.57% relative viability at 1 µM, 30.14% at 10 µM, and 29.74% at 20 µM, compared to 65.57%, 
57.47%, and 40.47%, respectively, at the same concentrations when delivered in ethanolic solutions.  
3.4 - Effect of E-BA and BA on Viability of B16-F10 Melanoma Cells 
In B16-F10 cells treated with BA, a similar effect was observed as with BE. E-BA and BA both 
induced a concentration-dependent reduction in relative cell viability (Figure 8). For E-BA at 
concentrations of 0.1, 1, 10, and 20 µM, the relative viability of cells was 76.67%, 37.00%, 26.54% and 
29.58%, compared to 88.59%, 69.80%, 59.39%, and 44.98%, respectively, in ethanolic solutions of BA. 
Of all treatments, 10 µM E-BA was the most effective. 
3.5 - Effect of E-TE and TE on Viability of B16-F10 Melanoma Cells 
For ease of comparison, all TE concentrations are presented in µM units assuming the same 
molecular weight as BE (442.72 g/mol) since the triterpene extract is composed mainly of BE, with most 
other components having similar molecular weights. The actual concentrations corresponding to 0.1, 1, 
10, and 20 µM are 0.23 µg/mL, 2.23 µg/mL, 22.6 µg/mL, and 45.2 µg/mL, respectively. TE showed the 
least toxicity towards B16-F10 cells among all treatments. E-TE and TE induced concentration-dependent 
reduction of cell viability (Figure 9), with the highest cytotoxicity observed in TE at a concentration of 20 
µM, in which the relative cell viability was determined to be 37.69% in comparison to 52.48% with 20 
µM E-TE. This was the only concentration among all drug treatments in which the ethanolic solution out-
performed the ethosomal solution of the same concentration. The relative cell viability at E-TE 
concentrations of 0.1, 1, and 10 µM were 79.60%, 60.35%, and 55.82%, respectively. In comparison, the 
relative cell viabilities for TE at the same concentrations were 89.70%, 73.76%, and 70.64%, 
respectively. The IC50 values, which represent the concentration of drug at which cell growth was 
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inhibited by 50%, were determined for all treatments based on individual dose-response curves (Table 6). 
The IC50 value was lower for E-BE and E-BA compared to ethanolic solutions of BE and BA, indicating 
an improvement in cytotoxic effect as a result of incorporation into the ethosomal system. The IC50 value 
for E-TE was higher than for ethanolic solutions of TE, suggesting that no improvement in cytotoxicity 




Figure 7: Effect of E-BE and BE on cell viability of B16-F10 cells.  Viability of cells treated with 
ethanolic-BE and ethosomal-BE was determined by measuring the activity of mitochondrial 
dehydrogenases using MTT colourimetric assay. B16-F10 melanoma cells seeded in 96-well plates at a 
density of 10,000 cells/well were treated with increasing concentrations of BE formulations for 48 hours 
and incubated with MTT reagent during the final 4 hours of treatment after which absorbance was 
measured at 570 nm. Cell viability was assessed relative to control cells. Each data represents the mean ± 
SD (n=3). 



























Figure 8: Effect of E-BA and BA on cell viability of B16-F10 cells. Viability of cells treated with 
ethanolic-BA and ethosomal-BA was determined by measuring the activity of mitochondrial 
dehydrogenases using MTT colourimetric assay. B16-F10 melanoma cells seeded in 96-well plates at a 
density of 10,000 cells/well were treated with increasing concentrations of BE formulations for 48 hours 
and incubated with MTT reagent during the final 4 hours of treatment after which absorbance was 
measured at 570 nm. Cell viability was assessed relative to control cells. Each data represents the mean ± 
SD (n=3). 
 
Figure 9: Effect of E-TE and TE on cell viability of B16-F10 cells. Viability of cells treated with 
ethanolic-TE and ethosomal-TE was determined by measuring the activity of mitochondrial 
dehydrogenases using MTT colourimetric assay. B16-F10 melanoma cells seeded in 96-well plates at a 
density of 10,000 cells/well were treated with increasing concentrations of BE formulations for 48 hours 
and incubated with MTT reagent during the final 4 hours of treatment after which absorbance was 
measured at 570 nm. Cell viability was assessed relative to control cells. Each data represents the mean ± 
SD (n=3). * = concentrations assuming same molecular weight as BE (442.7 g/mol).  


















































Table 6: Cytotoxic effect of birch bark triterpenes on B16-F10 melanoma cells.  B16-F10 melanoma 
cells were treated for 48 hours with BE, BA, or TE delivered in ethosomes or in ethanolic solutions. 



















IC50 = concentration of drug at which cell growth was inhibited by 50% 
 
3.6 - Effect of Ethosomal Triterpenes on Cellular Tyrosinase Activity in B16-F10 Melanoma Cells 
To investigate the effects of BE, BA, and TE on cellular tyrosinase activity, B16-F10 cells were 
treated with 10 nM solutions of the triterpenes both in ethosomes and in ethanolic solutions, a 
concentration at which the compounds would not affect the viability of the cells (Figure 9). All treatments 
caused a moderate reduction in the relative activity of tyrosinase, and although ethosomal solutions 
caused more of a reduction in relative activity, there were no significant differences between ethosomal 
and ethanolic treatments at such low concentrations. Cells treated with 10 nM E-BE showed relative 
tyrosinase activity of 72.53%, compared to 81.60% when treated with BE. Similarly, 10 nM E-BA 
showed relative tyrosinase activity of 71.67% compared to 79.23% for BA. Cells treated with 10 nM 
solutions of TE showed the least effect, with relative tyrosinase activity of 77.97% in E-TE and 83.15% 
relative activity in TE. For comparison, B16-F10 cells were also treated with kojic acid, a standard 
tyrosinase inhibitor, at concentrations from 1-500 µM (Figure 10). Kojic acid was found to reduce cellular 
tyrosinase activity in a concentration-dependent manner. Though it had no effect at 1 and 10 µM, the 






Figure 10: Effects of birch bark triterpenes on cellular tyrosinase activity. B16-F10 cells seeded at 
10,000 cells/well in 96-well plates were treated with 10 nM BE, BA, and TE in ethosomes and ethanolic 
solutions for 48 hours in the presence of 100 µM IBMX. Following treatment, cells were incubated with 
L-DOPA for 2 hours after which absorbance was measured at 490 nm. Tyrosinase activity was assessed 
relative to control cells. Each data represents the mean ± SD (n=3). 
 
 
Figure 11: Effect of kojic acid on cellular tyrosinase activity. B16-F10 cells seeded at 10,000 
cells/well in 96-well plates were treated with increasing concentrations of kojic acid for 48 hours in the 
presence of 100 µM IBMX. Following treatment, L-DOPA was added to wells for 2 hours after which 
absorbance was measured at 490 nm. Tyrosinase activity was assessed relative to control cells. Each data 
represents the mean ± SD (n=3). 













































Betulin (BE) and betulinic acid (BA) are readily extracted from North American birch species of 
the boreal forest, and have been reported to show significant cytotoxicity towards human and animal 
melanoma cell lines [62]–[64]. Despite their promising bioactivity and established low toxicity towards 
normal cells, their use in pharmaceuticals and cosmetics has traditionally been limited by their poor 
hydrosolubility. A common strategy that has been employed to overcome poor hydrosolubility of 
compounds is encapsulating them in a specialized vehicle to improve their hydrosolubility and 
bioavailability. Ethosomes, an ethanolic variation of the well-established drug carrier liposomes, have 
recently been used to encapsulate hydrophobic compounds [116], improve transdermal drug delivery 
[118], as well as improve the anti-melanoma effect and skin-lightening effect of various compounds [1], 
[44]. Because of their established potential as vehicles for drug delivery, especially in topical 
applications, ethosomes were investigated as a drug delivery vehicle for BE, BA, as well as a triterpene 
extract (TE) from the outer bark of Betula papyrifera.  
The main factors influencing the characteristics of ethosomal formulations in terms of vesicle size 
and entrapment efficiency are ethanol (EtOH) and phospholipid concentration. In order to determine a 
suitable formulation for encapsulating BE, BA, and TE in ethosomes, an optimization study was carried 
out using a range of EtOH and phospholipid (in this case DPPC) concentrations. In total, nine 
formulations were prepared with combinations of EtOH concentrations of 30%, 40%, and 50% v/v, and 
DPPC concentrations of 0.2%, 0.3%, and 0.4% w/v. Most commonly, phospholipid concentration in 
ethosomal formulations ranges from 0.5-5.0%, but is very much dependent on the type of phospholipid 
used. DPPC has been used in ethosomal formulations at concentrations ranging from 0.1-3.0% w/v [6], 
[131]. Preliminary work based on the physical appearance of formulations in this study was conducted in 
which DPPC concentrations of 0.5-1.0% resulted in the formation of a gel-like colloidal suspension upon 
sonication. Alternatively, concentrations ranging from 0.1-0.2% resulted in formulations that were 
inconsistent in stability and physical appearance. Therefore, DPPC concentrations ranging from 0.2- 0.4% 
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were used in the optimization study to investigate the effects of DPPC concentration on vesicle size and 
entrapment efficiency (Table 3). In the same preliminary work, EtOH concentrations ranging from 20% to 
60% v/v were examined. It was observed that concentrations of 20% were incapable of solubilizing all 
components of the lipid phase (DPPC, cholesterol, BE), while concentrations of 60% appeared to disrupt 
the lipid vesicles. Thus, EtOH concentrations ranging from 30-50% v/v were used to investigate the 
effects of EtOH concentration on vesicle size and entrapment efficiency. Using BE as a model drug for 
encapsulation at a concentration of 2 mg/mL (4.52 mM), nine formulations in total were prepared in 
triplicate, composed of different combinations of DPPC and EtOH concentrations (Table 3), and 
characterized based on their mean vesicle size and entrapment efficiency (Table 4). In order to improve 
stability, cholesterol and Tween-80 were included in ethosomal formulations. Cholesterol, which is 
known to prevent aggregation of vesicles as well as increase the rigidity of membranes in liposomes and 
ethosomes [107], was used at a concentration of 0.5 mg/mL (approximately 20% of the total phospholipid 
concentration). This conferred some stabilizing effect while maintaining the malleability of the lipid 
bilayer as observed in SEM images (Figure 3-6). Tween-80 was included at a concentration of 1 µL/mL 
in formulations (approximately 30% of total phospholipid concentration), which provided a sufficient 
stabilizing effect compared to solutions prepared without Tween-80. It was observed that the inclusion of 
cholesterol and Tween-80 prolonged the stability of the formulations and prevented separation over time. 
The ethosomes produced in the optimization study ranged in size from 3.67 - 15.08 µm, which is 
larger than most reported sizes for ethosomal systems. However, when employing particle size analysis, it 
is important to understand how the data reflects the actual sample. Particle sizes distributions can be 
generated by several models, but are most commonly measured as a number or a volume distribution 
[132]. Each technique generates a different result because each technique measures different properties of 
the sample [132]. In the case of a number distribution, each particle has equal weighting towards the 
distribution regardless of size or volume. With volume distributions, larger particles contribute 
significantly more towards the distribution because their volume/mass is taken into account. Thus, the 
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mean of a volume distribution will generally be higher than the mean of a number distribution generated 
from the same set of data. Particle analyzers that measure samples on the basis of laser diffraction, such as 
the one used in this study, construct their result as a volume distribution, therefore the sizes reported in 
this study represent the mean value of a volume distribution. As a result, despite the presence of a 
majority of smaller particles in the range of 50 nm as determined by SEM (Figures 3-6), the presence of 
larger particles in the micron range will shift the average towards the largest particles. If data sets were 
represented as a number distribution, the mean vesicle size of ethosome formulation would likely have 
been more representative of the smaller particles. However, this is not to say that a large mean vesicle size 
is unfavourable. Though smaller vesicles may offer advantages in terms of circulation and permeability, 
larger vesicles can generally incorporate a much higher payload of the active compound. In one of the few 
studies involving encapsulation of BA in a liposome, Mullauer et al. (2011) found that small liposomes 
ranging in size from 100-200 nm were capable of incorporating no more than 1 mg/mL [133]. When they 
produced larger liposomes ranging from 1-1.5 µm, they found that they were able to incorporate up to 6 
mg/mL of BA.  
In most reported cases, the size of ethosomes increases as the concentration of phospholipid 
increases [117], however in this study there was no definitive trend observed. On average, the ethosomes 
prepared with 0.3% DPPC yielded the lowest vesicle sizes (3.67 – 6.67 µm), followed by ethosomes 
prepared with 0.2% DPPC (8.27 – 10.21 µm), and the largest ethosomes on average were prepared with 
0.4% DPPC (6.67 – 15.08 µm). A similar trend was observed in a study by Bodade et al. (2013), in which 
ethosomes were prepared with 0.1%, 0.2%, and 0.3% DPPC and the smallest vesicle sizes were observed 
in formulations containing 0.2% DPPC, suggesting that in the lower range of phospholipid 
concentrations, a linear trend between vesicle size and phospholipid concentration is not always observed 
[6]. With regards to EtOH, a more predictable effect took place, in which increasing the concentration of 
EtOH while maintaining DPPC concentration resulted in smaller vesicle sizes in all cases except 
formulation F (50% EtOH, 0.3% DPPC, 4.22 µm), which was marginally larger than formulation E (40% 
38 
 
EtOH, 0.3% DPPC, 3.67 µm). Again, the same trend was observed by Bodade et al. (2013), in which 
increasing EtOH concentrations (25%, 35%, 45%) yielded smaller vesicles while the DPPC concentration 
was maintained at either 0.1%, 0.2%, or 0.3% DPPC [6]. EtOH’s ability to reduce vesicular size has been 
attributed to the EtOH hydrocarbon chain’s ability to interpenetrate the vesicular bilayer and reduce 
membrane thickness, while other reports suggest the reduction in size stems from the modified net charge 
that ethanol confers which provides some degree of steric stabilization [112], [117]  
There are few reports of the encapsulation of BA in liposomal carriers [133]–[137], and even 
fewer on the encapsulation of BE [138]. There are no studies investigating the biological effects of 
liposome containing BE, although it has been suggested due to the enhanced anti-tumour effect of BE 
when delivered in combination with cholesterol [70]. To the best of the author’s knowledge, this study 
represents the first time BE and BA have been incorporated into ethosomes (or transethosome) and is the 
first investigation of the bioactivity and/or encapsulation of The Actives Factory Triterpene Extract (TE). 
Using the optimized formulation which contained 0.3% DPPC and 40% EtOH, ethosomes were prepared 
containing BE, BA, and TE. The triterpenes and phospholipids were incorporated at a molar ratio of 
approximately 1:1 (50 molar %) in order to attain the highest concentration of triterpenes in the lipid 
bilayers of the ethosomes. In order to remove any un-entrapped drug, solutions were filtered through 10 
µm nylon filters following preparation. Following filtration, >90% of the drug remained in ethosomal 
solutions (Table 4). The entrapment efficiencies in this study correspond well with a recent report in 
which Guo et al. (2017) produced folate-functionalized BA-liposomes with an entrapment efficiency of 
91.61 % [137]. Prior to cell treatments, ethosomal solutions were further filtered through 0.8 µm nylon 
filters to remove any larger vesicles, and the drug content of the formulations was re-measured by HPLC. 
Following the filtration through 0.8 µm membranes, the drug concentration in formulations was still 
above 80% of the original amount added in all formulations. The re-calculated entrapment efficiency was 
94.50% for BE-ethosomes, 88.14% for BA-ethosomes, and 83.64% for TE-ethosomes, with any loss in 
drug content attributed to the larger ethosomes which were removed by filtration. This suggests that the 
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vast majority of BE, BA, and TE was entrapped within the smaller vesicles which were not lost during 
filtration, especially in BE-ethosomes which only lost ~1% of drug content during the filtration step. 
Former studies reported that DPPC-triterpene liposomes were capable of entrapping only small amounts 
of triterpene constituents in lipid bilayer (~ 10 molar %) [138], but these results suggest that ethosomes 
are capable of entrapping triterpenes at much higher molar ratios.  
The treatment of B16-F10 melanoma cells with BE, BA, and TE resulted in a concentration-
dependent decrease in cell viability as determined by the MTT assay (Figure 7-9), a commonly used 
method of measuring in vitro cytotoxicity [139]. For each compound, cells were treated in the range of 
0.1 µM to 20 µM, which was selected based on former reports of the effects on BE and BA on the B16-
F10 cell line [63]. Based on dose-response curves for ethosomal and ethanolic solutions of BE, BA, and 
TE, the IC50 values were determined for all treatments, which represents the concentration of the 
compound that inhibited cell growth by 50% (Table 6). BE and BA both had a significant cytotoxic effect 
on B16-F10 cells, with IC50 values of 14.38 µM and 16.41 µM, respectively, which correspond well with 
former reports of the compounds’ effects on B16-F10 melanoma cells. Gauthier et al. (2006) investigated 
several lupane type triterpenes including BE and BA and their cytotoxic effects on three cancerous cell 
lines including B16-F10 [63]. The reported IC50 values for BE and BA in their study were 13.8 µM and 
16.1 µM, respectively. In that study, the authors attempted to enhance the pharmacological properties of 
the compounds via the addition of sugar moieties at the C-3 or C-28 position, which resulted in a loss of 
cytotoxicity for BE but improved the IC50 of BA to 3.9 µM in B16-F10 cells. These results confirm BE 
and BA as potent cytotoxic agents. The cytotoxic effect of TE (IC50 = 36.00 µg/mL) was quite similar to 
that of BE (IC50 = 32.50 µg/mL) and BA (IC50 = 35.90 µg/mL), which was expected based on its 
composition which mainly consists of BE (65%), and considerable BA content (7%) (Table 2). The 
presence of other triterpene compounds in the extract such as lupeol, which accounts for 7% of the 
extract, may have hindered its cytotoxic effect against B16-F10 cells, as it has been shown to be inactive 
against both human and mouse melanoma cells lines [63]. The effects of other betulin derivatives in the 
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extract such as betulin aldehyde (2% content) are less studied on murine melanoma cells, but have been 
shown to exhibit distinct cytotoxicity towards human melanoma lines G361 and SK-MEL-28 with IC50 
values of 9.4 µM and 9.3 µM, respectively [62]. Hata et al. (2003) further showed that lupane triterpenes 
with an aldehyde group at C-17 selectively inhibited leukemia cell growth, and similar to with betulinic 
acid, the carbonyl group at C-17 is responsible for the inhibitory activities through the inhibition of 
topoisomerase I, a common target in chemotherapeutic agents. The interference of DNA topoisomerases, 
which are essential for DNA replication, will interfere with cell cycle and ultimately trigger cell death 
[140]. 
When delivered in ethosomes, the cytotoxic effect of BE and BA was improved at all 
concentrations (Figure 7-8). The IC50 value for E-BE was 2.43 µM compared to 14.38 µM when delivered 
in its free form in ethanolic solutions. The same effect was observed with E-BA (IC50 = 3.07 µM), which 
was more effective at all concentrations compared to BA in its free form in solution (IC50 = 16.41 µM). 
As previously mentioned, no studies to date, to the best of our knowledge, have investigated the effects of 
BE delivered in liposomes or ethosomes. However, there are several reports investigating BA delivered in 
liposomes to improve cytotoxic effect, the results of which align well with this study. BA was previously 
incorporated into liposomes and used to treat mice xenografted with human colon and lung cancer 
tumours [133]. In that study, BA-liposomes were delivered intravenously and reduced tumour growth by 
>50% compared with the control treatment (an empty liposome) but were not compared directly to free 
form BA in solution. More recently, Liu et al. (2016) modified BA-liposomes with PEG-2000, in which 
PEGylated BA-liposomes were shown to improve the bioavailability of BA, and showed higher cytotoxic 
effect in vitro and in vivo over both traditional BA-liposomes and BA in solution [136].  Ethosomes and 
liposomes have also been used as delivery systems for a variety of botanical extracts, including Aloe vera 
leaf extract [141], curcumin extract [142], seabuckthorn leaf extract [143], with generally promising 
results. In this case, the cytotoxic effect of TE was not significantly improved by delivery in ethosomes 
(Figure 9). Although E-TE showed moderate improvement in cytotoxic effect at 0.1, 1, and 10 µM, TE 
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was more effective in its free form at a concentration of 20 µM, which resulted in a lower IC50 value for 
TE in ethanolic solutions than E-TE. In the future, cell viability experiments will need to be assessed 
across a broader range of concentrations to evaluate the cytotoxic effects of TE. The improvement in anti-
melanoma effect observed in E-BE and E-BA suggests that the ethosome carriers facilitated increased 
uptake of the triterpenes into the cells over ethanolic solutions. Larger ethosomal vesicles would likely 
have fused with cellular membranes and released the triterpene contents into the cell, while smaller 
ethosomes may have been directly taken up by the cell through endocytosis [106].  
Ethosomes have recently been shown to improve the anti-melanogenic properties of compounds. 
Limsuwan et al. (2017) incorporated phenylethyl resorcinol (PR), a skin-lightening agent, into ethosomes 
and reported higher tyrosinase inhibition in B16 melanoma cells compared to PR delivered in liposomes 
and hydroethanolic solutions [8]. Briefly, ethosomal and ethanolic formulations of BE, BA, and TE were 
assessed for their ability to inhibit cellular tyrosinase in B16-F10 cells (Figure 10) and compared to a 
standard tyrosinase inhibitor kojic acid (Figure 11). Cells were treated with ethosomal triterpenes and 
ethanolic triterpenes in the presence of 100 µM 3-isobutyl-1-methylxanthine (IBMX), which is known to 
induce melanogenesis, leading to increased synthesis of tyrosinase [144]. Following treatment with test 
substances, L-DOPA was added to the wells and the oxidation of L-DOPA to dopaquinone, the precursor 
of melanin, was monitored at 490 nm. Because ethosomal triterpenes showed approximately 20-30% cell 
death at 0.1 µM concentrations, cells were treated with 10 nM solutions of the triterpenes in ethosomes 
and ethanolic solutions to avoid any significant effect on cell viability. Kojic acid was tested at a range of 
1-500 µM because it has been shown to have minimal effect on viability of B16-F10 cells up to 500 µM 
[145]. At such low concentrations, the effect on cellular tyrosinase of ethosomal and ethanolic triterpenes 
was only moderate, and there was no distinguishable improvement in effect conferred by the delivery in 
ethosomes at the selected concentration. Still, ethosomal triterpenes and ethanolic triterpenes at a 
concentration of 10 nM showed higher inhibition of cellular tyrosinase than the standard inhibitor kojic 
acid at 1-10 µM, which supports their use cosmetic and skin-lightening applications.  
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The results from this study are preliminary but indicate that ethosomes are a promising vehicle 
for improving the effects of triterpenes such as BE, BA, and TE. Ethosomes were shown to successfully 
encapsulate BE, BA, and TE with high entrapment efficiency. They were also shown to enhance anti-
melanoma effect of both BE and BA as demonstrated by their increased cytotoxicity towards B16-F10 
melanoma cells. Although there was no significant improvement in the anti-melanogenic effects of the 
triterpenes when delivered in ethosomes, further studies will have to be done across a broader range of 
treatments to elucidate the effects of ethosomal triterpenes on tyrosinase activity. The established 
therapeutic potential of these triterpenes towards a variety of afflictions affecting the skin combined with 
the proven capabilities of ethosomes as transdermal drug carriers support their use in the future 














Betulin and betulinic acid are pentacyclic triterpenes with selective cytotoxicity towards 
melanoma and established anti-melanogenic effects. Their poor hydrosolubility has hindered their 
attractiveness for use in pharmaceutical and cosmetic formulations. The results of this study demonstrate 
that these triterpenes can be incorporated into ethosomes with high efficiency to improve the potential 
delivery and bioavailability of these compounds. Furthermore, ethosomal formulations of BE and BA 
were shown to exhibit enhanced anti-melanoma effect in B16 melanoma cells when compared to their 
free forms in solution. A triterpene extract from Betula papyrifera was also investigated and shown to 
have similar cytotoxicity towards B16 melanoma cells as the pure triterpenes. The anti-melanogenic 
effects of betulin, betulinic acid, and the triterpene extract were assessed based on their ability to inhibit 
cellular tyrosinase in B16-F10 melanoma cells and were all shown to inhibit the activity of the enzyme 
more effectively than the standard control kojic acid, though no improvement in anti-melanogenic effect 
was observed when the compounds were delivered in ethosomes. These preliminary results suggest that 
further studies examining the use of ethosomal carriers for the delivery of these triterpenes are warranted, 
and the potential of these compounds as anti-melanoma and anti-melanogenic agents should be further 
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Microtrac Flex / Microtrac S3500 Particle Analyzer Data (Vesicle Size) 
Table A.1: BE-ethosome particle analysis tabular data from Microtrac Flex software. 
  A B C 
1       
2       
3 ID1:  Betulin (3/3)   
4 ID2:  -   
5 Date:  02/09/2018   
6 Time:  16:13   
7 DB Rec:  266   
8 DB Name:  C:\Program Files\Microtrac FLEX 10.3.15\Databases\MTDatabase.MDB 
9 Summary Data 
10   MV(um): 2.450 
11   MN(um): 1.449 
12   MA(um): 1.501 
13   CS: 4.00 
14   SD: 0.1150 
15       
16   Mz: 1.483 
17   si: 0.1201 
18   Ski: 0.01142 
19   Kg: 1.077 
20 User Defined Calculations 
21   Name Value 
22 Formula 1:      
23 Formula 2:      
24 Formula 3:      
25 Percentiles 
26   %Tile Size(um) 
27   10.00 1.327 
28   20.00 1.386 
29   30.00 1.421 
30   40.00 1.452 
31   50.00 1.482 
32   60.00 1.512 
33   70.00 1.545 
34   80.00 1.581 
35   90.00 1.624 
36   95.00 1.691 
37 Size Percent 
38   Size(um) %Tile 
39       
40       
41       
42       
43       
44       
45       
46       
47       
48       
49 Peaks 
50 Dia(um) Vol % Width 
51 68.7300 1.20 18.2500 
52 3.7700 1.60 17.2100 




Table A.2: BA-ethosome particle analysis tabular data from Microtrac Flex software. 
  A B C 
1       
2       
3 ID1:  Betulinic Acid (2/3)   
4 ID2:  -   
5 Date:  02/08/2018   
6 Time:  19:20   
7 DB Rec:  235   
8 DB Name:  C:\Program Files\Microtrac FLEX 10.3.15\Databases\MTDatabase.MDB 
9 Summary Data 
10   MV(um): 4.63 
11   MN(um): 1.275 
12   MA(um): 2.146 
13   CS: 2.795 
14   SD: 2.547 
15       
16   Mz: 3.45 
17   si: 3.46 
18   Ski: 0.543 
19   Kg: 1.647 
20 User Defined Calculations 
21   Name Value 
22 Formula 1:      
23 Formula 2:      
24 Formula 3:      
25 Percentiles 
26   %Tile Size(um) 
27   10.00 1.122 
28   20.00 1.236 
29   30.00 1.355 
30   40.00 1.840 
31   50.00 2.875 
32   60.00 3.65 
33   70.00 4.42 
34   80.00 5.50 
35   90.00 9.86 
36   95.00 15.47 
37 Size Percent 
38   Size(um) %Tile 
39       
40       
41       
42       
43       
44       
45       
46       
47       
48       
49 Peaks 
50 Dia(um) Vol % Width 
51 25.3200 5.00 18.8200 
52 11.0900 7.40 4.6900 
53 3.9700 46.40 2.7770 
54 1.2420 41.20 0.4000 
55       
57 
 
Table A.3: TE-ethosomes particle analysis tabular data from Microtrac Flex software. 
  A B C 
1       
2       
3 ID1:  Triterpene Extract (2/3)   
4 ID2:  -   
5 Date:  02/09/2018   
6 Time:  16:41   
7 DB Rec:  276   
8 DB Name:  C:\Program Files\Microtrac FLEX 10.3.15\Databases\MTDatabase.MDB 
9 Summary Data 
10   MV(um): 2.947 
11   MN(um): 1.783 
12   MA(um): 2.419 
13   CS: 2.480 
14   SD: 1.269 
15       
16   Mz: 2.828 
17   si: 1.249 
18   Ski: 0.2213 
19   Kg: 0.902 
20 User Defined Calculations 
21   Name Value 
22 Formula 1:      
23 Formula 2:      
24 Formula 3:      
25 Percentiles 
26   %Tile Size(um) 
27   10.00 1.478 
28   20.00 1.701 
29   30.00 1.969 
30   40.00 2.348 
31   50.00 2.726 
32   60.00 3.08 
33   70.00 3.46 
34   80.00 3.91 
35   90.00 4.63 
36   95.00 5.41 
37 Size Percent 
38   Size(um) %Tile 
39       
40       
41       
42       
43       
44       
45       
46       
47       
48       
49 Peaks 
50 Dia(um) Vol % Width 
51 3.2500 70.70 2.1360 
52 1.5800 29.30 0.4720 
53       
54       
58 
 
Table A.4: Blank Ethosomes particle analysis tabular data from Microtrac Flex software. 
  A B C 
1       
2       
3 ID1:  Blank (3/3)   
4 ID2:  -   
5 Date:  02/08/2018   
6 Time:  20:05   
7 DB Rec:  251   
8 DB Name:  C:\Program Files\Microtrac FLEX 10.3.15\Databases\MTDatabase.MDB 
9 Summary Data 
10   MV(um): 3.45 
11   MN(um): 1.392 
12   MA(um): 1.501 
13   CS: 4.00 
14   SD: 0.1520 
15       
16   Mz: 1.442 
17   si: 2.926 
18   Ski: 0.473 
19   Kg: 37.25 
20 User Defined Calculations 
21   Name Value 
22 Formula 1:      
23 Formula 2:      
24 Formula 3:      
25 Percentiles 
26   %Tile Size(um) 
27   10.00 1.250 
28   20.00 1.313 
29   30.00 1.364 
30   40.00 1.406 
31   50.00 1.445 
32   60.00 1.483 
33   70.00 1.524 
34   80.00 1.569 
35   90.00 1.629 
36   95.00 20.02 
37 Size Percent 
38   Size(um) %Tile 
39       
40       
41       
42       
43       
44       
45       
46       
47       
48       
49 Peaks 
50 Dia(um) Vol % Width 
51 35.7900 6.00 29.4300 
52 1.4340 94.00 0.2800 





Figure A.1: Particle size distribution of BE-ethosomes produced by Microtrac Flex software 
 
 















Table A.5: Mean vesicle size data from ethosome formulations produced in optimization study as 
determined using diffraction particle analysis (Microtrac Flex software). 
Formulation MV(um) SD (um) Avg (um) SD (um) 
A1 10.36 6.45 
  
A2 6.51 2.511 
  
A3 13.77 7.61 10.21333 3.632222 
B1 10.15 6.15 
  
B2 7.46 5.34 
  
B3 7.88 4.74 8.496667 1.447147 
C1 7.76 3.66 
  
C2 10.23 7.93 
  
C3 6.83 5.09 8.273333 1.757166 
D1 6.76 3.36 
  
D2 9.16 6.24 
  
D3 4.09 1.482 6.67 2.536198 
E1 3.58 0.937 
  
E2 3.67 1.311 
  
E3 3.78 2.35 3.676667 0.100167 
F1 4.76 1.802 
  
F2 4.65 1.934 
  
F3 3.25 1.33 4.22 0.841843 
G1 16.98 11.32 
  
G2 12.87 6.85 
  
G3 15.39 8.78 15.08 2.072462 
H1 11.32 5.72 
  
H2 12.21 4.7 
  
H3 9.46 9.27 10.99667 1.403222 
I1 7.95 1.326 
  
I2 6.7 1.268 
  
I3 5.36 1.244 6.67 1.295261 
 
Table A.6: Vesicle size data from ethosomes containing triterpenes determined using diffraction particle 
analysis (Microtrac Flex software). 
Formulation MV(um) SD (um) Avg (um) SD (um) 
Betulin 3.71 2.209 
  
 
3.87 1.261    
2.45 0.115 3.343333 0.777775      
Betulinic Acid 5.03 2.978 
  
 
4.63 2.547    
5.66 3.51 5.106667 0.519262      
Triterpene Extract 2.388 0.917   
 2.947 1.269   
 2.372 0.913 2.569 0.327455      
Blank 3.68 0.145 
  
 
4.25 0.134    




HPLC Data (Entrapment Efficiency) 
Standard curves for BE, BA, and TE: 
 
Figure A.5: Relationship between BE concentration (mg/mL) and peak area as determined by HPLC. 
 
Figure A.6: : Relationship between BA concentration (mg/mL) and peak area as determined by HPLC. 
 
 
Figure A.7: Relationship between TE concentration (mg/mL) and peak area as determined by HPLC. 
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Table A.7: HPLC retention times, peak areas, corresponding concentrations calculated from standard 
curve of BE, and entrapment efficiencies of ethosome formulations used in optimization study.  
Formulation RT Peak Area Conc (mg/mL) EE % Avg EE% Std Dev 
A1 4.209 68.1 0.027990157 98.62117 
  
A2 4.173 70.9 0.029592537 98.51294 
  
A3 4.171 86.1 0.038291175 98.07582 98.40331 0.288732 
B1 4.200 1141 0.641988097 68.83553 
  
B2 4.179 184.5 0.094603411 95.81401 
  
B3 4.180 159.8 0.080468124 96.84439 96.3292 0.728588 
C1 4.193 726.9 0.40500744 85.05508 
  
C2 4.172 100.2 0.046360307 97.84371 
  
C3 4.178 55.3 0.020664988 99.01595 93.97158 7.74413 
D1 4.182 285.7 0.152518027 92.17856 
  
D2 4.183 430.9 0.235612911 89.71123 
  
D3 4.181 337.4 0.182104841 91.87032 91.25337 1.344398 
E1 4.181 153.2 0.076691084 96.24063 
  
E2 4.189 211.8 0.110226622 94.77599 
  
E3 4.182 145.3 0.072170081 96.26062 95.75908 0.85144 
F1 4.172 106.7 0.050080119 97.79383 
  
F2 4.182 101.8 0.047275953 97.94452 
  
F3 4.177 121.7 0.058664301 96.86287 
  
F4 4.185 78.6 0.033999084 98.381 
  
F5 4.191 89.7 0.040351379 98.2902 
  
F6 4.174 130.7 0.063814811 96.69353 97.66099 0.71907 
G1 4.188 492.8 0.271036969 88.2668 
  
G2 4.182 290.2 0.155093281 92.57927 
  
G4 4.182 308.7 0.16568044 91.41552 
  
G4 4.176 375.5 0.203908664 89.64931 
  
G5 4.209 683.4 0.380113311 80.80236 
  
G6 4.188 375.8 0.204080348 89.31517 88.6714 4.153502 
H1 4.179 434.6 0.237730342 88.89111 
  
H2 4.181 209.5 0.108910381 94.6873 
  
H3 4.183 110.1 0.052025867 97.38563 93.65468 4.34039 
I1 4.164 39.7 0.011737438 99.4384 
  
I2 4.191 83.9 0.037032162 98.1106 
  







Table A.8: HPLC peak areas, corresponding concentrations calculated from standard curves of BE, BA, 





Conc (mg/mL) EE% Avg EE% SD 
1 153.2 0.076691084 96.24063 
  
2 211.8 0.110226622 94.77599 
  
3 145.3 0.072170081 96.26062 95.75908 0.85144 
BA-ethosomes      
1 1066.6 0.120123511 93.99382 
  
2 1243.3 0.140968149 92.95159   
3 1036.7 0.116596319 94.17018 93.7052 0.658574 
TE-ethosomes      
1 701.5 0.128351164 93.61437 
  
2 755.8 0.138001066 93.23524   
3 747.8 0.13657935 93.17103 93.34021 0.239586 
 
 
Table A.9: HPLC peak areas and corresponding concentrations calculated from standard curves of BE, 
BA, and TE of final solutions filtered through 0.8 µm prior to cell treatments. 
Compound Peak Area Conc (mg/mL) 
Betulin 14472.9 1.889935746 
Betulinic Acid 12449.9 1.762877473 
















MTT Assay Data (Anti-melanoma Effect) 
Relative Cell Viability = (ABSsample – ABSblank)/(ABScontrol – ABSblank)*100 
ABSblank = average of 3 blank wells     ABScontrol = average of 3 control wells 
 
Table A.10: ABS570 values from MTT assay for determination of cell viability of B16-F10 cells treated 
with ethosomal-BE, ethosomal-BA, and ethosomal-TE for 48 hours.  
 Eth-BE   Eth-BA   Eth-TE   
 ABS Corrected 
% 
Viability ABS Corrected 
% 
Viability ABS Corrected % Viability 
0.1 µM 0.955 0.840667 76.93716 1.057 0.942667 86.27212 0.917 0.814333 70.40347 
 0.871 0.756667 69.24955 0.976 0.861667 78.85907 0.946 0.843333 72.91068 
 0.773 0.658667 60.28067 0.82 0.705667 64.58207 1.207 1.104333 95.47553 
Avg   68.82246   76.57109   79.59656 
SD   8.336456   11.02455   13.80861 
          
1 µM 0.541 0.426667 39.04822 0.597 0.482667 44.17329 0.815 0.712333 61.58502 
 0.446 0.331667 30.3539 0.407 0.292667 26.78465 0.693 0.590333 51.03746 
 0.686 0.571667 52.3185 0.552 0.437667 40.05493 0.894 0.791333 68.415 
Avg   40.57354   37.00429   60.34583 
SD   11.06146   9.086862   8.75479 
          
10 µM 0.48 0.365667 33.46555 0.426 0.311667 28.52351 0.722 0.619333 53.54467 
 0.396 0.281667 25.77794 0.372 0.257667 23.58148 0.679 0.576333 49.82709 
 0.455 0.340667 31.17757 0.415 0.300667 27.5168 0.844 0.741333 64.09223 
Avg   30.14035   26.5406   55.82133 
SD   3.947367   2.61164   7.400062 
          
20 µM 0.408 0.293667 26.87617 0.416 0.301667 27.60832 0.704 0.601333 51.98847 
 0.387 0.272667 24.95426 0.408 0.293667 26.87617 0.695 0.592333 51.21038 
 0.523 0.408667 37.40087 0.467 0.352667 32.2758 0.73 0.627333 54.23631 
Avg   29.74377   29.57598   52.47839 
SD   6.700513   3.818117   1.571333 
 
Table A.11: Sample microplate ABS570 readings from PowerWave XS Microplate Spectrophotometer 
for 1, 10, and 20 µM ethosomal solutions of  BE and BA (light grey), solvent control (dark grey), and 
blank (cross-hatching) 
0.04 0.04 0.041 0.04 0.04 0.041 0.04 0.04 0.041 0.041 0.041 0.04 
0.045 0.408 0.48 0.541 0.955 1.534 1.585 1.176 1.133 1.32 1.643 0.041 
0.044 0.387 0.396 0.446 0.871 1.063 1.268 0.952 0.798 1.518 0.968 0.045 
0.048 0.523 0.455 0.686 0.773 1.463 1.109 1.112 0.98 1.33 0.99 0.046 
0.048 0.416 0.426 0.597 1.057 0.111 0.867 0.663 0.797 1.3 1.261 0.049 
0.05 0.408 0.372 0.407 0.976 0.117 0.746 0.841 0.87 1.255 1.205 0.05 
0.051 0.467 0.415 0.552 0.82 0.115 1.035 1.022 1.157 1.438 1.155 0.051 




Table A.12: ABS570 values of wells containing formazan from MTT assay for determination of cell 
viability of B16-F10 cells treated with ethosomal-BE, ethosomal-BA, and ethosomal-TE for 48 hours. 
 BE   BA   TE   
 ABS Corrected % Viability ABS Corrected % Viability ABS Corrected % Viability 
0.1 µM 0.826 0.718333 93.04832 0.781 0.722 93.52332 0.503 0.407 79.36307 
 0.779 0.671333 86.96023 0.653 0.545333 70.63899 0.538 0.442 86.1879 
 0.666 0.558333 72.32293 0.892 0.784333 101.5975 0.627 0.531 103.5425 
Avg   84.11049   88.58661   89.69782 
SD   10.65252   16.05884   12.46598 
          
          
1 µM 0.814 0.735 63.78365 0.987 0.908 78.79667 0.861 0.782 67.86233 
 0.735 0.656 56.92799 0.847 0.768 66.6474 1.076 0.997 86.52013 
 0.955 0.876 76.01969 0.816 0.737 63.95721 0.85 0.771 66.90774 
Avg   65.57711   69.80043   73.7634 
SD   9.671384   7.906236   11.05796 
          
          
10 µM 0.713 0.634 55.01882 0.656 0.577 50.07233 1.072 0.993 86.17301 
 0.736 0.657 57.01477 0.812 0.733 63.61008 0.734 0.655 56.84121 
 0.775 0.696 60.39921 0.822 0.743 64.47789 0.873 0.794 68.90369 
Avg   57.4776   59.38677   70.6393 
SD   2.719891   8.078201   14.74272 
          
          
20 µM 0.607 0.528 45.82009 0.535 0.456 39.57189 0.541 0.462 40.09258 
 0.521 0.442 38.35697 0.688 0.609 52.84931 0.493 0.414 35.92711 
 0.508 0.429 37.22882 0.569 0.49 42.52243 0.506 0.427 37.05526 
Avg   40.46863   44.98121   37.69165 
SD   4.668703   6.971845   2.154417 
 
 
Table A.13: Microplate ABS570 readings from PowerWave XS Microplate Spectrophotometer for 1, 10, 
and 20 µM ethanolic solutions of  BE, BA, and TE (light grey), solvent control (dark grey), and blank 
(cross-hatching). 
0.04 0.04 0.041 0.041 0.042 0.041 0.041 0.041 0.042 0.042 0.041 0.041 
0.047 0.588 0.607 0.713 0.814 2.148 1.695 1.83 2.007 1.238 1.04 0.041 
0.044 0.603 0.521 0.736 0.735 2.581 1.921 3.132 2.137 1.941 1.277 0.045 
0.047 0.501 0.508 0.775 0.955 2.266 2.153 3.297 1.999 1.475 1.377 0.046 
0.048 0.07 0.767 0.656 0.987 0.079 0.639 0.541 1.072 0.861 1.625 0.051 
0.127 0.704 0.758 0.812 0.847 0.076 0.502 0.493 0.734 1.076 2.845 0.05 
0.051 0.83 0.681 0.822 0.816 0.082 0.62 0.506 0.873 0.85 2.605 0.052 


















Figure A.8: Dose response curves generated by ED50plus V1.0 software used to calculate IC50 values for 
all treatments. Group 1 = BE, Group 2 = BA, Group 3 = TE, Group 4 = E-BE, Group 5 = E-BA, Group 6 
= E-TE. 
 
Table A.14: Relative cell viabilities of B16-F10 cells (response) corresponding to each treatment (dose) 
as determined by MTT assay after 48 hour treatment.  
 Response 
Dose BE BA TE E-BE E-BA E-TE 
0.1 µM 84.11 88.58661 89.69782 68.82246 76.57109 79.59656 
1 µM 65.57 69.80043 73.7634 40.57364 37.00429 60.34583 
10 µM 57.4776 59.38677 70.6393 30.14035 26.5406 55.82133 
20 µM 40.46863 44.98121 37.69165 29.74377 29.57598 52.47839 





































Cellular Tyrosinase Activity Data (Anti-melanogenic Effect) 
Relative Tyrosinase Activity = (ABSsample – ABSblank)/(ABScontrol – ABSblank)*100 
ABSblank = average of 3 blank wells     ABScontrol = average of 3 control wells 
 
Table A.15: ABS490 values of wells containing dopaquinone, the product of L-DOPA oxidation by 
tyrosinase as measure of relative tyrosinase activity in B16-F10 cells treated with BE, BA, and TE for 48 
hours in the presence of 100 µM IBMX. 
 ABS Corrected % Activity 
0.01 µM BE 0.3 0.239333 79.60095 
 0.292 0.231333 76.94019 
 0.326 0.265333 88.24842 
  Avg 81.59652 
  SD 5.912338 
0.01 µM BA 0.339 0.278333 92.57216 
 0.277 0.216333 71.95127 
 0.281 0.220333 73.28165 
  Avg 79.26836 
  SD 11.54061 
0.01 µM TE 0.285 0.224333 74.61203 
 0.303 0.242333 80.59874 
 0.344 0.283333 94.23513 
  Avg 83.14863 
  SD 10.05699 
 
 
Table A.16: Microplate ABS490 readings from PowerWave XS Microplate Spectrophotometer for 1 nM 
BE, BA, and TE ethanolic solutions and 1-500 µM KA (light grey), solvent controls (dark grey), and 
blank (cross-hatching). 
0.043 0.041 0.042 0.041 0.042 0.042 0.042 0.042 0.043 0.044 0.042 0.046 
0.049 0.3 0.334 0.323 0.342 0.352 0.285 0.302 0.243 0.246 0.181 0.042 
0.047 0.27 0.274 0.318 0.311 0.213 0.303 0.301 0.231 0.262 0.216 0.054 
0.055 0.346 0.347 0.42 0.323 0.325 0.344 0.373 0.261 0.311 0.241 0.047 
0.052 0.339 0.403 0.381 0.42 0.06 0.371 0.372 0.286 0.166 0.124 0.058 
0.06 0.277 0.403 0.375 0.401 0.062 0.384 0.351 0.261 0.184 0.131 0.055 
0.053 0.281 0.323 0.272 0.371 0.06 0.351 0.353 0.245 0.159 0.144 0.061 







Table A.17: ABS490 values of wells containing dopaquinone, the product of L-DOPA oxidation by 
tyrosinase as measure of relative tyrosinase activity in B16-F10 cells treated with 1-500 µM KA for 48 
hours in the presence of 100 µM IBMX. 
 ABS Corrected % Activity 
1 µM KA 0.371 0.310333 103.2152 
 0.384 0.323333 107.5389 
 0.351 0.290333 96.5633 
  Avg 102.4391 
  SD 5.528818 
10 µM KA 0.372 0.311333 103.5478 
 0.351 0.290333 96.5633 
 0.353 0.292333 97.22849 
  Avg 99.11319 
  SD 3.854851 
100 µM KA 0.286 0.225333 74.94462 
 0.261 0.200333 66.62975 
 0.245 0.184333 61.30823 
  Avg 67.62753 
  SD 6.872735 
250 µM KA 0.166 0.105333 35.03323 
 0.184 0.123333 41.01994 
 0.159 0.098333 32.70506 
  Avg 36.25274 
  SD 4.289487 
500 µM KA 0.124 0.063333 21.06424 
 0.131 0.070333 23.3924 
 0.144 0.083333 27.71614 
  Avg 24.05759 
  SD 3.37547 
 
